Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

ination with Capecitabine in Patients with Advanced Breast Cancer.
  • Patricia Gomez, M.D., Breast Cancer Center, Vall d'Hebron University Hospital, Barcelona, Spain
  • Abstract 1083, General Poster Session, Breast Cancer Track
  • Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2

"With more than 70 investigator and company sponsored studies being presented at ASCO, we look forward to continuing our work with investigators to understand how Nexavar may fit into other areas of the therapeutic landscape, particularly with respect to how biomarkers status may guide selection of therapy, which is a step toward personalized medicine," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals.  

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 90 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by other companies, international study groups, government agencies a
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Seoul Semiconductor announced ... various applications in the lighting market. In ... of this technology in emerging markets such as ... wide range of applications such as streetlight and ... lighting. , First launched in 2005 the Acrich ...
(Date:4/23/2015)... 2015 /CNW/ - A new and innovative service has ... North America,s largest packaging trade ... in the "Sustainability, service" category of the PAC ... Comparison" is a service that scores clients, packaging ... peers. This benchmarking process shows clients how their ...
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology and medical device industries, ... the United States , today announced ... quarter of 2015 after the New York Stock Exchange ... Thursday morning, May 14, 2015 Shanghai time). The earnings ...
(Date:4/23/2015)... 2015 Prospects for Leading Companies ... Report Details   We predict the global ... billion in 2015 and will grow at a CAGR of ... sectors around the world and increasing functional requirements for healthcare ... the global healthcare packaging market. A global ageing ...
Breaking Biology Technology:Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10
... March 11 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ... focused on researching, developing, manufacturing and marketing,biopharmaceutical products, today ... fiscal year ended December 31, 2008. , , ... -- Total net revenues increased 35.0% over 2007 ...
... Instrument, a world-leading flow measurement and control provider, ... controller, a totally new family of mass flow ... pressure and temperature. Built on a standard 1.125-inch ... local digital display, the B-Series provides a compact ...
... DR-70 cancer testTUSTIN, Calif., March 11 AMDL, Inc. ... major operations in China, announced today it has entered ... a clinical study for the validation of AMDL,s ... cancer test.Through this validation study, AMDL and Mayo Clinic ...
Cached Biology Technology:3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 23SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 33SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 43SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 53SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 63SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 73SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 83SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 93SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 103SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 113SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 123SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 133SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 143SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 153SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 163SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 173SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 183SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 193SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 203SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 213SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 223SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 233SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results 24Brooks Instrument's New Mass Flow Controller Series Is Immune to Pressure and Temperature Fluctuations 2Brooks Instrument's New Mass Flow Controller Series Is Immune to Pressure and Temperature Fluctuations 3AMDL, Inc. Enters Into Collaboration Agreement to Advance Development of Its AMDL DR-70 (FDP) Cancer Test 2AMDL, Inc. Enters Into Collaboration Agreement to Advance Development of Its AMDL DR-70 (FDP) Cancer Test 3
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... elaborate heterotrimeric G-protein network known to date in the ... principal investigator at the Danforth Plant Science Center. ... recent article, "An elaborate heterotirmeric G-protein family from soybean ... New Phytologist . G-proteins are signaling proteins that ...
... An alliance of top researchers at the University ... Biology Institute (SBI), advancing efforts to engineer cells and ... in health and medicine, energy, the environment, new materials, ... The new institute aiming to create "an industrial ...
... Gullmar fjord on the Swedish west coast, reveal that when ... sustainable fishing methods and earn far more. His research at ... fishing fleet can be reduced. , Transferrable fishing rights ... only for species such as herring and mackerel. A report ...
Cached Biology News:UC Berkeley launches Synthetic Biology Institute to advance research in biological engineering 2UC Berkeley launches Synthetic Biology Institute to advance research in biological engineering 3Putting a price on sea fish 2Putting a price on sea fish 3
...
Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
... offered in several versions. The Captiva 0.2 ... are ideal to prepare precipitated protein samples ... and necessary to prevent clogging of expensive ... fiber and 20 um polypropylene filter plates ...
... Cy5 Post-Labeling Reactive Dye Pack, ... CyDye fluors specifically optimized for microarray ... 40000 pmol reactive dye per vial, ... to use, individually dispensed, and packed ...
Biology Products: